Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Aurora, a Public-Private RNA CDMO, Opens in Australia

publication date: Sep 13, 2024

Aurora Biosynthetics, a Sidney company, launched to offer manufacturing services for RNA therapeutics to the Asia-Pacific region. Aurora is a division of Myeloid Therapeutics, a three-year-old RNA company headquartered in Cambridge, Mass. Aurora is a public-private partnership between the New South Wales Government, which contributed $200m Australian ($134m US) for the construction; RNA Australia; and Myeloid Therapeutics. The facility will supply Myeloid with its own RNA products, while Aurora will also manufacture products for other companies. Terms of the partnership were not disclosed. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here